Collegium Pharmaceutical Inc
NASDAQ:COLL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Collegium Pharmaceutical Inc
NASDAQ:COLL
|
US |
|
China Reform Culture Holdings Co Ltd
SSE:600636
|
CN |
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
US |
|
D
|
DigiPlus Interactive Corp
XPHS:PLUS
|
PH |
Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
Record Results: Collegium achieved record net revenues of $780.6 million, up 24% year-over-year, and record adjusted EBITDA of $460.5 million, up 15%.
Jornay PM Growth: Jornay PM prescriptions grew 20% year-over-year, with net revenue up 48% to $148.9 million; prescribers reached an all-time high.
Pain Portfolio: Pain medicines generated $631.7 million in revenue, up 6% year-over-year, and showed signs of long-term durability.
Cash Strength: Operating cash flow exceeded $329 million, with year-end cash at $386.7 million—up $223.9 million from last year.
Shareholder Returns: The company repurchased $25 million in shares and closed a $980 million credit facility, improving financial flexibility.
2026 Guidance: Management reaffirmed 2026 guidance for total product revenues of $805–825 million and Jornay revenue of $190–200 million, projecting more than 30% annual growth for Jornay.
Payer Access & Marketing: New formulary access will increase Jornay's coverage by 4.5 million lives starting in May; digital and sales force investments are driving awareness and demand.
